These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28413961)

  • 41. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence.
    Kawanami D; Matoba K; Sango K; Utsunomiya K
    Int J Mol Sci; 2016 Jul; 17(8):. PubMed ID: 27483245
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Beyond glycemic control: cardiovascular effects of incretin-based therapies.
    Angeli FS; Shannon RP
    Front Horm Res; 2014; 43():144-57. PubMed ID: 24943305
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
    Matikainen N; Mänttäri S; Schweizer A; Ulvestad A; Mills D; Dunning BE; Foley JE; Taskinen MR
    Diabetologia; 2006 Sep; 49(9):2049-57. PubMed ID: 16816950
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of GLP-1 based therapies on diabetic dyslipidemia.
    Patel VJ; Joharapurkar AA; Shah GB; Jain MR
    Curr Diabetes Rev; 2014; 10(4):238-50. PubMed ID: 24998439
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Incretin hormones and maturity onset diabetes of the young--pathophysiological implications and anti-diabetic treatment potential.
    Østoft SH
    Dan Med J; 2015 Sep; 62(9):. PubMed ID: 26324089
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Perspectives in GLP-1 Research: New Targets, New Receptors.
    Cantini G; Mannucci E; Luconi M
    Trends Endocrinol Metab; 2016 Jun; 27(6):427-438. PubMed ID: 27091492
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Incretin hormones in the treatment of type 2 diabetes. Part II. Incretins - new possibilities for pharmacotherapy of type 2 diabetes].
    Matuszek B; Lenart-Lipińska M; Nowakowski A
    Endokrynol Pol; 2008; 59(4):322-9. PubMed ID: 18777503
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Physiology and pathophysiology of incretins in the kidney.
    von Websky K; Reichetzeder C; Hocher B
    Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):54-60. PubMed ID: 24257158
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cardiovascular Effects of Incretin-Based Therapies.
    White WB; Baker WL
    Annu Rev Med; 2016; 67():245-60. PubMed ID: 26768240
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity.
    Opinto G; Natalicchio A; Marchetti P
    Arch Physiol Biochem; 2013 Oct; 119(4):170-8. PubMed ID: 23859800
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Potential new approaches to modifying intestinal GLP-1 secretion in patients with type 2 diabetes mellitus: focus on bile acid sequestrants.
    Holst JJ; McGill MA
    Clin Drug Investig; 2012 Jan; 32(1):1-14. PubMed ID: 21958333
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Intestinal lipid absorption and transport in type 2 diabetes.
    Vergès B
    Diabetologia; 2022 Oct; 65(10):1587-1600. PubMed ID: 35908083
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Blood pressure-lowering effects of incretin-based diabetes therapies.
    Lovshin JA; Zinman B
    Can J Diabetes; 2014 Oct; 38(5):364-71. PubMed ID: 25284699
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of incretin-based therapies on renal function.
    Tsimihodimos V; Elisaf M
    Eur J Pharmacol; 2018 Jan; 818():103-109. PubMed ID: 29066413
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
    Vergès B; Bonnard C; Renard E
    Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice.
    Hsieh J; Longuet C; Baker CL; Qin B; Federico LM; Drucker DJ; Adeli K
    Diabetologia; 2010 Mar; 53(3):552-61. PubMed ID: 19957161
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.
    Panchapakesan U; Mather A; Pollock C
    Clin Sci (Lond); 2013 Jan; 124(1):17-26. PubMed ID: 22963445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incretin therapies in the management of elderly patients with type 2 diabetes mellitus.
    Bourdel-Marchasson I; Schweizer A; Dejager S
    Hosp Pract (1995); 2011 Feb; 39(1):7-21. PubMed ID: 21441754
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The entero-insular axis in type 2 diabetes--incretins as therapeutic agents.
    Creutzfeldt W
    Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S288-303. PubMed ID: 11460578
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.